6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052

SOURCES SOUGHT NOTICE (36C25027Q0052) Low Energy Radiopharmaceuticals (Non-FDG F-18 Agents), Unit Doses VA Northeast Ohio Healthcare System (Cleveland, OH) and VA Kent Imaging and Infusion Center (Kent, OH) Notice Type: Sources Sought (Market Research Only) Contracting Office: Department of Veterans Affairs NAICS Code: 325412 Pharmaceutical Preparation Manufacturing Small Business Size Standard: 1,300 employees Product Service Code (PSC): 6505 Drugs and Biologicals Place of Performance: Hot Lab Room B-C432, 10701 East Blvd., Cleveland, OH 44106; and Hot Lab Room B109, 3838 Cascades Blvd., Kent, OH 44240 Anticipated Period of Performance: Base: 01/01/2027 12/31/2027, plus four (4) 12-month option years (through 12/31/2031) Response Due Date/Time: 9:00 AM Eastern Time, Tuesday, November 3, 2026 to: Robert.Blasko@va.gov 1. PURPOSE / DISCLAIMER This is a Sources Sought Notice (SSN) issued for market research purposes only in accordance with FAR Part 10. It is NOT a solicitation, a request for proposal, a request for quotation, or an invitation for bid, and it does not commit the Government to issue a solicitation or award any contract. The Government will not pay for any information submitted in response to this notice, and responses will not be returned. Submitting a response does not guarantee participation in any future solicitation. The purpose of this notice is to identify qualified sources including the extent of participation by Service-Disabled Veteran-Owned Small Businesses (SDVOSBs), Veteran-Owned Small Businesses (VOSBs), and other small business concerns capable of meeting the requirement described below. Responses will assist the Government in determining the appropriate acquisition strategy (including any Veterans First / Rule of Two set-aside determination under VAAR 819.70) and will be used to support acquisition planning under FAR Part 10 and VAAR Part 810. This requirement is being conducted under the VA's health-care-resources sharing authority at 38 U.S.C. 8153 and Public Law 104-262. 2. BACKGROUND AND SCOPE The VA Northeast Ohio Healthcare System and the VA Kent Imaging and Infusion Center require unit-dose, patient-specific low energy radiopharmaceutical products (non-fluorodeoxyglucose F-18 agents) to support routine (non-emergent) and emergent diagnostic nuclear medicine imaging and limited therapeutic procedures. All doses must be compounded and calibrated by or under the supervision of a certified Nuclear Pharmacist and prepared within the required guidelines of the Board of Pharmacy, specifically USP and USP as appropriate. The contractor must follow generally accepted industry standards and the regulations of the applicable governing bodies, which may include the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the Food and Drug Administration (FDA), the Nuclear Regulatory Commission (NRC), the Centers for Disease Control and Prevention (CDC), the United States Pharmacopeia (USP), and The Joint Commission (JC). Delivery requirement: The contractor must support both routine and emergent orders (Emergencies). Emergencies may be requested during and outside of regular work hours (Monday through Friday, 06:30 a.m. 4:30 p.m.) and require delivery within 120 minutes after receipt of a phoned, faxed, or electronic order from the VA. The VA also requires prompt processing of Tc-99m tagged white blood cell (WBC) orders. Quantities are estimates and may vary based on patient demand. 3. REQUIRED LICENSURE STATEMENT Interested parties must already possess all licenses, registrations, and authorizations required to receive, possess, compound, prepare, transport, distribute, and dispose of the radioactive byproduct material / radiopharmaceutical isotopes described in this notice, and must be regularly established in the business of providing radionuclides. At a minimum, respondents must hold a current, unrevoked Nuclear Regulatory Commission (NRC) and/or applicable Agreement State radioactive materials license authorizing production and distribution of radiopharmaceuticals for human administration, and the authority to receive and dispose of radioactive waste, together with all applicable FDA, U.S. Department of Transportation (DOT), and state and local authorizations. Respondents should confirm they currently hold such licensure (and, where applicable, identify the issuing authority and license type) as part of their response. Respondents are not required to submit the full license with this SSN but must affirmatively state that current, valid licensure is in place; copies may be required at the solicitation/award stage. 4. ESTIMATED REQUIREMENT (ANNUAL ESTIMATES) The following unit-dose radiopharmaceutical products are required. Quantities are annual estimates based on historical usage for one year and may vary based on patient demand. Item Description Est. Annual Qty 1 99mTc Sulfur Colloid 320 2 99mTc MDP 850 3 99mTc Mebrofenin 110 4 99mTc MAG-3 80 5 99mTc Tetrofosmin 10 6 99mTc MAA 75 7 111In Pentreotide 2 8 99mTc04- (Sodium Pertechnetate) 90 9 99mTc Sestamibi 5,000 10 99mTc White Blood Cell Labeling 90 11 111In White Blood Cell Labeling 2 12 99mTc DTPA 30 40 mCi 60 13 99mTc DTPA 0.4 0.7 mCi 5 14 I-123 Iodine Capsules 200 microcuries 90 15 I-123 Iodine Capsules 2 5 millicuries 12 16 UltraTag Kit 22 17 99mTc Filtered Sulfur Colloid: 0.5 1 millicurie 6 18 123I MIBG dose 2 19 Cold PYP vials 50 20 99mTc PYP 100 21 99mTc DMSA 2 22 67Ga Gallium Citrate 2 23 111In DTPA 2 24 99mTc HMPAO 2 25 131I Diagnostic capsule 10 26 131I Therapeutic capsule 1 3 mCi 12 27 131I Therapeutic capsule, each additional mCi 1,500 28 99mTc HDP 55 29 99mTc WBC Blood Kit (Heparin) 90 Products must be labeled with the radiopharmaceutical identity, amount/activity, concentration, preparation time, calibration time, total volume, expiration date and time, and must include a bar-code label to facilitate scanning into a Nuclear Medicine Information System (NMIS). Each syringe, vial, syringe shield, and vial shield must be correctly labeled. 5. INFORMATION REQUESTED FROM RESPONDENTS Interested and capable firms are invited to submit a response demonstrating their ability to meet this requirement. Responses must include ALL of the following: Manufacturer Authorized Distribution Letter(s) documentation establishing the respondent's authorization to distribute the applicable radiopharmaceutical product(s) (e.g., authorized distributor/dealer letter(s) from the manufacturer(s)). Manufacturer's Name(s) identify the manufacturer(s) of the radiopharmaceutical product(s) the respondent would supply. Business Size and Socioeconomic Status state whether the firm is a large or small business under NAICS 325412 (1,300-employee size standard), and identify all applicable socioeconomic categories (e.g., SDVOSB, VOSB, 8(a), HUBZone, WOSB, SDB, or other). SDVOSBs/VOSBs must be certified in the SBA Veteran Small Business Certification program (via the SBA Search for Certified Businesses (SBS)). Ability to Provide ALL Items state clearly whether the firm can provide ALL of the items listed in Section 4. If the firm can provide only a portion, identify specifically which item(s) it can and cannot supply. GSA / NAC / SAC Availability state whether the item(s) are available on a GSA Schedule, a VA National Acquisition Center (NAC) contract, or a VA Strategic Acquisition Center (SAC) / MSPV contract vehicle, and provide the applicable contract number(s) if so. SAM Unique Entity Identifier (UEI) provide the firm's SAM.gov UEI. Respondents must be actively registered in SAM.gov (www.sam.gov). Current Licensure Confirmation an affirmative statement that the firm currently holds all required NRC and/or Agreement State, FDA, and DOT licenses/authorizations to receive, compound, prepare, transport, distribute, and dispose of the radiopharmaceutical isotopes described herein (see Section 3), including the issuing authority and license type where applicable. Positive Acknowledgement of Delivery Capability a positive, affirmative statement that the firm can deliver in accordance with ALL SOW requirements, including the ability to fulfill emergent orders within 120 minutes of receipt to both the Cleveland and Kent locations, and to provide unit doses compounded/calibrated by or under a certified Nuclear Pharmacist in accordance with USP / and all applicable NRC/FDA/DOT/state regulations. Respondents are encouraged to identify the location(s) of the radiopharmacy(ies) from which they would service both sites. Additional information requested (optional but helpful): company name, address, point of contact (name, title, phone, email); a brief capability statement; and any relevant prior experience providing unit-dose radiopharmaceuticals to federal or commercial healthcare customers. 6. SUBMISSION INSTRUCTIONS Response due date/time: 9:00 AM Eastern Time, Tuesday, November 3, 2026. Responses received after this date and time may not be considered. Format: Submit responses…